Expression of matrix metalloproteinase-1, -7, -9, -13, Ki-67, and HER-2 in epithelial-myoepithelial salivary gland cancer

Head and Neck

Volumn 32, Issue 8, 2010, Pages 1019-1027

  Luukkaa, Heikki ^a   Klemi, Pekka ^b   Leivo, Ilmo ^c   Mäkitie, Antti A ^a,d   Irish, Jonathan ^e   Gilbert, Ralph ^e   Perez Ordonez, Bayardo ^f   Hirsimäki, Pirkko ^b   Vahlberg, Tero ^b   Kivisaari, Atte ^b,g   Kähäri, Veli Matti ^b,g   Grénman, Reidar ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g UNIVERSITY OF TURKU   (Finland)

Author keywords

Epithelial myoepithelial carcinoma; HER 2; Ki 67; Matrix metalloproteinase; MMP; Salivary gland cancer

Indexed keywords

COLLAGENASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE B; INTERSTITIAL COLLAGENASE; KI 67 ANTIGEN; MATRILYSIN;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COHORT STUDIES; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MATRIX METALLOPROTEINASES, SECRETED; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SALIVARY GLAND NEOPLASMS;

EID: 77955613720     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21277     Document Type: Article

References (51)

1. Donath K, Seifert G, Schmitz R. Diagnosis and ultrastructure of the tubular carcinoma of salivary gland ducts. Epithelial-myoepithelial carcinoma of the intercalated ducts. [Article in German.] Virchows Arch A Pathol Pathol Anat 1972;356:16-31.
2. Ellis GL, Auclair PL. Atlas of Tumor pathology: tumors of the salivary glands. Washington, DC: Armed Forces Institute of Pathology; 1996. p 163.
3. Luukkaa H, Klemi P, Leivo I, et al. Salivary gland cancer in Finland 1991-96: an evaluation of 237 cases. Acta Otolaryngol 2005;125:207-214.
4. Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumors. Lyon; 2005.
5. Fonseca I, Soares J. Epithelial-myoepithelial carcinoma of the salivary glands. A study of 22 cases. Virchows Arch A Pathol Anat Histopathol 1993;422:389-396.
6. De S, Fenton JE, Jones AS. Matrix metalloproteinases and their inhibitors in non-neoplastic otorhinolaryngological disease. J Laryngol Otol 2005;119:436-442.
7. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-21494.
8. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-839.
9. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174.
10. Ala-aho R, Kähäri VM. Collagenases in cancer. Biochimie. 2005;87:273-286.
11. Vihinen P, Ala-aho R, Kähäri VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005;5:203-220.
12. Westernoff TH, Jordan RC, Regezi JA, Ramos DM, Schmidt BL. Beta-6 Integrin, tenascin-C, and MMP-1 expression in salivary gland neoplasms. Oral Oncol 2005;41:170-174.
13. Soini Y, Autio-Harmainen H. Synthesis and degradation of basement membranes in benign and malignant salivary gland tumours. A study by in situ hybridization. J Pathol 1993;170:291-296.
14. Azuma M, Tamatani T, Fukui K, et al. Role of plasminogen activators, metalloproteinases and the tissue inhibitor of metalloproteinase-1 in the metastatic process of human salivary-gland adenocarcinoma cells. Int J Cancer 1993;54:669-676.
15. Freitas VM, Scheremeta B, Hoffman MP, Jaeger RG. Laminin-1 and SIKVAV a laminin-1-derived peptide, regulate the morphology and protease activity of a human salivary gland adenoid cystic carcinoma cell line. Oral Oncol 2004;40:483-489.
16. Kayano K, Shimada T, Shinomiya T, et al. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2. J Pathol 2004;202:403-411.
17. Nagel H, Laskawi R, Wahlers A, Hemmerlein B. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland. Histopathology 2004;44:222-231.
18. Luukkaa H, Klemi P, Hirsimäki P, et al. Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer. Acta Otolaryngol 2008;128:482-490.
19. Saarialho-Kere UK, Crouch EC, Parks WC. Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol 1995;105:190-196.
20. Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999;286:113-117.
21. Skalova A, Lehtonen H, von Boguslawsky K, Leivo I. Prognostic significance of cell proliferation in mucoepidermoid carcinomas of the salivary gland: clinicopathological study using MIB 1 antibody in paraffin sections. Hum Pathol 1994;25:929-935. (Pubitemid 24292411)
22. Skalova A, Leivo I, Von Boguslawsky K, Saksela E. Cell proliferation correlates with prognosis in acinic cell carcinomas of salivary gland origin. Immunohistochemical study of 30 cases using the MIB 1 antibody in formalin-fixed paraffin sections. J Pathol 1994;173:13-21. (Pubitemid 24182256)
23. Hellquist HB, Sundelin K, Di Bacco A, Tytor M, Manzotti M, Viale G. Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki-67 and bcl-2 expression and of in situ end labelling (TUNEL). J Pathol 1997;181:323-329.
24. Nordgård S, Franzén G, Boysen M, Halvorsen TB. Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections. Laryngoscope 1997;107:531-536.
25. Kiyoshima T, Shima K, Kobayashi I, et al. Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands. Oral Oncol 2001;37:315-322.
26. Xin W, Paulino AF. Prognostic factors in malignant mixed tumors of the salivary gland: correlation of immunohistochemical markers with histologic classification. Ann Diagn Pathol 2002;6:205-210.
27. Luukkaa H, Klemi P, Leivo I, Vahlberg T, Grénman R. Prognostic significance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: an evaluation of 212 cases. Acta Oncol (Stockholm, Sweden) 2006;45:669-675.
28. Skálová A, Stárek I, Vanecek T, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2003;42:348-356.
29. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006;24:2673-2678.
30. Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 2007;29:907-912.
31. Williams MD, Roberts D, Blumenschein GR Jr, et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 2007;31:1645-1652.
32. Johnson CJ, Barry MB, Vasef MA, Deyoung BR. Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Appl Immunohistochem Mol Morphol 2008;16:54-58.
33. Di Palma S, Skálová A, Vanìèek T, Simpson RH, Stárek I, Leivo I. Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. Histopathology 2005;46:144-152.
34. Matsubayashi S, Yoshihara T. Carcinoma ex pleomorphic adenoma of the salivary gland: an immunohistochemical study. Eur Arch Otorhinolaryngol 2007;264:789-795.
35. Dodd RL, Slevin NJ. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol 2006;42:759-769.
36. Sugano S, Mukai K, Tsuda H, et al. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 1992;102:923-927.
37. Nguyen LH, Black MJ, Hier M, Chauvin P, Rochon L. HER2/neu and Ki-67 as prognostic indicators in mucoepidermoid carcinoma of salivary glands. J Otolaryngol 2003;32:328-331.
38. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003;39:724-727.
39. Cho KJ, El-Naggar AK, Ordonez NG, Luna MA, Austin J, Batsakis JG. Epithelial-myoepithelial carcinoma of salivary glands. A clinicopathologic, DNA flow cytometric, and immunohistochemical study of Ki-67 and HER-2/neu oncogene. Am J Clin Pathol 1995;103:432-437.
40. Press MF, Pike MC, Hung G, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994;54:5675-5682.
41. Haapasalo H, Pesonen E, Collan Y. Volume corrected mitotic index (M/V-INDEX). The standard of mitotic activity in neoplasms. Pathol Res Pract 1989;185:551-554.
42. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004;10:4793-4798.
43. Riedel F, Götte K, Schwalb J, Bergler W, Hörmann K. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol 2000;17:1099-1105.
44. O-Charoenrat P, Rhys-Evans P, Eccles S. A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops. Int J Cancer 2002;100:527-533.
45. Johansson N, Airola K, Grénman R, Kariniemi AL, Saarialho-Kere U, Kähäri VM. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997;151:499-508.
46. Luukkaa M, Vihinen P, Kronqvist P, et al. Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck 2006;28:225-234.
47. Airola K, Johansson N, Kariniemi AL, Kähäri VM, Saarialho-Kere UK. Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol 1997;109:225-231.
48. Impola U, Jeskanen L, Ravanti L, et al. Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds. Br J Dermatol 2005;152:720-726.
49. Kivisaari AK, Kallajoki M, Mirtti T, et al. Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas. Br J Dermatol 2008;158:778-785.
50. López-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7:800-808.
51. Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007:26:717-724.